

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Anke Stabenau et al.

Application No.: 10/591,098

Confirmation No.: 6371

Filed: July 18, 2007

Art Unit: 1611

For: PHARMACEUTICAL COMPOSITION FOR  
TOPICAL USE IN FORM OF XEROGELS  
OR FILMS AND METHODS FOR  
PRODUCTION

---

Examiner: T. M. Love

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

An abstract translation of the non-English language references are enclosed.

An English counterpart for Japanese Application No. JP 2002-504084 is cited (see US Patent Number cite no. 1). Likewise an English counterpart for Japanese Application No. JP 10-512892 is cited (see US Patent Number cite no. 2).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 66188(310089).

Dated: September 12, 2011

Respectfully submitted,

Electronic signature: /Dwight D. Kim, Ph.D./  
Dwight D. Kim, Ph.D.

Customer No. 21874

Registration No.: 57,665  
EDWARDS ANGELL PALMER & DODGE  
LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 517-5588  
Attorneys/Agents For Applicant